NewsFlash Archive

more Events

Subscribe

  • 0%
    0 votes

    Penn Researchers Find Genetic Link to Leukemias With an Unknown Origin

    Friday, February 19, 2010

    PHILADELPHIA -- Although leukemia is one of the best studied cancers, the cause of some types is still poorly understoodNow, a newly found mutation in acute myeloid leukemia patients could account for half of the remaining cases of adult acute leukemia with an unknown origin"The molecular biology

    read more>>

  • 0%
    0 votes

    EntreMed Receives Orphan Drug Designation for ENMD-2076 in Leukemia

    Wednesday, February 17, 2010

    ROCKVILLE, MD -- EntreMed, Inc. (Nasdaq: ENMD), today announced that the U.S. Food and Drug Administration (FDA) has granted orphan drug designation for the Company’s lead oncology drug candidate, ENMD-2076, for the treatment of acute myeloid leukemia (AMLThe FDA accepted EntreMed’s a

    read more>>

  • 0%
    0 votes

    A Variant of the Gene GFI1 Predisposes to a Subtype of Blood Cancer

    Wednesday, January 20, 2010

    Montréal -- A large international research group led by Dr. Tarik Möröy, a researcher at the Institut de recherches cliniques de Montréal (IRCM), has discovered that a variant of the gene "Growth Factor Independence 1" (GFI1) predisposes humans to develop acute myeloid This

    read more>>

  • 0%
    0 votes

    Drug That Modifies Gene Activity Could Help Some Older Leukemia Patients

    Wednesday, January 13, 2010

    Older patients with acute myeloid leukemia (AML) might benefit from a drug that reactivates genes that cancer cells turn off, according to research at Washington University School of Medicine in St. Louis and collaborating institutionsThe researchers say the findings support further investigation

    read more>>

  • 0%
    0 votes

    Researchers Discover Genetic Differences Between Lethal and Treatable Forms of Leukemia

    Friday, January 8, 2010

    NEW YORK  -- A tumor's genetic profile is often useful when diagnosing and deciding on treatment for certain cancers, but inexplicably, genetically similar leukemias in different patients do not always respond well to the same therapyWeill Cornell Medical College researchers believe they may

    read more>>

  • 0%
    0 votes

    Xenomics, Inc., and Its Subsidiary TrovaGene, Inc., Announce Italian Patent for NPM1 Testing for AML Patients

    Wednesday, December 16, 2009

    Xenomics, Inc. (Pink Sheets: XNOM), a developer of transrenal molecular diagnostics, announced today that a key Italian patent covering a unique diagnostic application with critical significance for patients with acute myeloid leukemia (AML) has issuedThe patent, entitled: “Nucleophosmin pro

    read more>>

  • 0%
    0 votes

    A New Target for Lymphoma Therapy

    Thursday, December 10, 2009

    Researchers at the Program in Cellular and Molecular Medicine and the Immune Disease Institute at Children's Hospital Boston (PCMM/IDI) have found a link between a common mutation that can lead to cancer and a distant gene regulator that enhances its activityDiscovery of this relationship could le

    read more>>

  • 0%
    0 votes

    Children Who Survive Cancer More Likely to Suffer From Heart Disease

    Thursday, December 10, 2009

    Children and adolescents who survive cancer have a significantly higher risk of developing heart disease as young adults, according to the largest study on this issue published on bmj.com todayThe findings show that young adult survivors of childhood cancer are at risk for a variety of cardiovascu

    read more>>

  • 0%
    0 votes

    First-in-Class Treatment for Acute Leukemia

    Wednesday, December 9, 2009

    EUREKA project E! 3172 NKSTIM has produced a new potential drug to stimulate cancer patients' own 'natural killer' cells to attack and eliminate cancer cells; currently undergoing clinical testing in patients with leukaemia or myelomaExisting knowledge of how transplanted bone marrow cells eradica

    read more>>

  • 0%
    0 votes

    Genzyme's Mozobil Shows Promise in Chemosensitization

    Wednesday, December 9, 2009

    CAMBRIDGE, Mass. -- Genzyme Corporation (Nasdaq: GENZ) announced today that a Phase 1/2 trial provided early clinical data suggesting that Mozobil® (plerixafor injection) in combination with chemotherapy may offer a therapeutic impact on leukemic cells protected in bone marrowThe investigation

    read more>>